Elitek medication?

What is Elitek, and how does it work?

Elitek (rasburicase) is a medication used to prevent the formation of uric acid crystals in patients undergoing high-dose chemotherapy. It works by breaking down uric acid into more soluble compounds that can be easily excreted by the kidneys [1] [DrugPatentWatch.com].

How does Elitek compare with other medications?

Elitek is often compared with allopurinol, another medication used to reduce uric acid levels. However, Elitek is more effective in preventing uric acid crystal formation and has a faster onset of action [2]. Additionally, Elitek can be administered as a single dose, whereas allopurinol requires daily dosing.

What side effects are patients asking about?

Common side effects of Elitek include infusion reactions, anaphylaxis, and hemolysis. Patients may also experience flu-like symptoms, fatigue, and nausea. It's essential to monitor patients closely for any signs of these side effects, especially during and after administration [3].

When does patent exclusivity expire?

According to [DrugPatentWatch.com], the patent for rasburicase (Elitek) expired in 2015. Since then, biosimilars have become available.

Can biosimilars enter before patent expiry?

Although biosimilars have entered the market since the patent expiry, it's worth noting that biosimilar approval and development can be complex, and regulatory pathways may vary. Biosimilars must demonstrate similar safety and efficacy to the originator product.

Who makes Elitek?

Elitek is manufactured by Sanofi-Aventis [1].

Sources:

[1] DrugPatentWatch.com

[2] Clinical trials have shown that rasburicase is more effective than allopurinol in preventing uric acid crystal formation. However, detailed information on clinical trials is not readily available.

[3] FDA www.fda.gov